Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban versus dalteparin before next-day ultrasound for suspected lower-extremity deep vein thrombosis
NL-OMON24892Recruiting
- Sponsor
- Zuyderland
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of rivaroxaban and dalteparin in deep vein thrombosis (DVT) (2 arms), sponsored by Zuyderland. Primary endpoints: Patient satisfaction, Physician satisfaction and 4 more. Started Jun 2021; status: recruiting.
02
Drugs
rivaroxabandalteparin
03
Conditions
deep vein thrombosis (DVT)
Beyond the preview
Go deeper on NL-OMON24892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24892.